Program
VSA012
A development code.
Its studies are mostly in Hemoglobinuria, Paroxysmal, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bisirna Therapeutics (Suzhou) | 22 open or running | phase 3since Sep 4, 2026 | Dec 29, 2024 | Sep 30, 2027phase 3 · NCT07816237 |
| Bisirna Therapeutics Pte. | 11 open or running | phase 1since Feb 17, 2025 | Feb 17, 2025 | Feb 28, 2027phase 1 · NCT06848296 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 29, 2024First study: phase 1 study in Healthy VolunteersNew to Bisirna Therapeutics (Suzhou)Bisirna Therapeutics (Suzhou) · NCT06766929 · 40 enrolled · China
- Feb 17, 2025Bisirna Therapeutics Pte.'s first study: phase 1 study in Hemoglobinuria, ParoxysmalNew to Bisirna Therapeutics Pte.Bisirna Therapeutics Pte. · NCT06848296 · 50 enrolled · China
- Sep 4, 2026Phase 3 study in Hemoglobinuria, ParoxysmalPhase 3 reachedBisirna Therapeutics (Suzhou) · NCT07816237 · 70 planned · China
Ahead
- Feb 28, 2027Primary completion: phase 1 study in Hemoglobinuria, ParoxysmalBisirna Therapeutics Pte. · NCT06848296
- Sep 30, 2027Primary completion: phase 3 study in Hemoglobinuria, ParoxysmalBisirna Therapeutics (Suzhou) · NCT07816237
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07816237Hemoglobinuria, Paroxysmal · China | 3 | Not yet recruiting | Bisirna Therapeutics (Suzhou) | Sep 30, 2027 | 70 |
| NCT06848296Hemoglobinuria, Paroxysmal · China | 1 | Active, not recruiting | Bisirna Therapeutics Pte. | Feb 28, 2027 | 50 |
| NCT06766929Healthy Volunteers · China | 1 | Active, not recruiting | Bisirna Therapeutics (Suzhou) | Aug 2026 | 40 |
How it is read
Names in the registry
- “VSA012”, 3 entries
Codes read as this program: VSA012.
Conditions, from the studies’ own filings
- Hemoglobinuria, Paroxysmal, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.